{"id":"ef47e9e07df9","type":"article","url":"https://hartvaat.nl/2026/07/31/atenolol-vermindert-postoperatief-atriumfibrilleren-na-hartchirurgie/","title":"Atenolol vermindert postoperatief atriumfibrilleren na hartchirurgie","title_en":"A meta-analysis of randomized controlled trials on atenolol's impact on postoperative atrial fibrillation in adults undergoing cardiac surgery.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":[],"journal":"Medicine","doi":"10.1097/MD.0000000000050029","source_url":"https://doi.org/10.1097/MD.0000000000050029","authors":["Jin-He Deng","Fan-Rong He","Yun-Tai Yao"],"significance":5,"published":"2026-08-15","source_date":"2026-07-31","image":"https://hartvaat.nl/global/img/0155cc89a708.webp","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/"],"congress":"","summary_en":"A meta-analysis of six randomized controlled trials (870 patients) demonstrates that atenolol significantly reduces the incidence of postoperative atrial fibrillation following cardiac surgery (RR 0.55; 95% CI 0.32-0.93). However, atenolol showed no superiority over sotalol and performed similarly to other control agents such as metoprolol and propafenone. These findings reinforce the established role of beta-blockers in POAF prophylaxis, without providing evidence to favor atenolol over alternative antiarrhythmic or beta-blocking strategies.","created":"2026-08-09T01:14:12Z","updated":"2026-08-10T10:35:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Een meta-analyse van zes RCTs (870 patiënten) toont aan dat atenolol het risico op postoperatief atriumfibrilleren (POAF) na een hartoperatie significant verlaagt (RR 0,55; 95% BI 0,32-0,93). Atenolol was niet superieur aan sotalol en vertoonde geen significant verschil met andere controlemedicatie zoals metoprolol of propafenon. Voor de klinische praktijk bevestigt dit onderzoek de rol van beta-blokkers bij POAF-profilaxe, zonder dat atenolol een duidelijk voordeel biedt ten opzichte van alternatieve opties.","abstract_original":"Prior research has conducted a limited number of studies on the efficacy of atenolol in preventing atrial fibrillation following cardiac surgery (CS). Consequently, a comprehensive evaluation and meta-analysis were undertaken to assess the effectiveness and safety of atenolol in patients undergoing CS for the prevention of postoperative atrial fibrillation (POAF). A meta-analysis of randomized controlled trials was performed. Searches were conducted across multiple databases up to December 1, 2024. The primary focus was the incidence of POAF. Risk ratios (RRs) for treatment effects on dichotomous variables were calculated. The data analysis encompassed 6 randomized controlled trials involving a total of 870 patients. The meta-analysis revealed that atenolol significantly reduces the incidence of POAF in adult patients undergoing CS (RR, 0.55; 95% confidence interval [CI]: 0.32-0.93; P = .03) with moderate heterogeneity (I2 = 57%; P = .10). Atenolol did not demonstrate superiority over sotalol in reducing POAF (RR, 2.39; 95% CI: 1.41-4.04; P = .001) with moderate heterogeneity (I2 = 40%; P = .19). Furthermore, no significant difference was observed between atenolol and the control group (comprising propafenone, metoprolol, nebivolol, and digoxin) in the prevention of POAF (RR, 1.28; 95% CI: 0.76-2.16; P = .35) with moderate heterogeneity (I2 = 43%; P = .15). Recent studies suggest that atenolol could be a safe and effective intervention for the prevention of POAF in adult patients undergoing CS."}